REVB Stock Analysis: Buy, Sell, or Hold?
REVB - Revelation Biosciences, Inc. Common Stock
$1.08
0.04 (3.85%)
▲
5d:
+12.5%
30d:
+1.89%
90d:
-12.2%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When REVB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: REVB shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: REVB shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: REVB is currently trading at $1.08, which is considered extended relative to its 30-day fair value range of $0.99 to $1.07.
Technical Outlook: Technically, REVB is in a downtrend. The price is approaching resistance at $1.11. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.8% recently.
Market Sentiment: REVB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $19.25 (+1682.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, REVB is in a downtrend. The price is approaching resistance at $1.11. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.8% recently.
Market Sentiment: REVB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $19.25 (+1682.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.99 -
$1.07
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
68.4%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.8%)
- BULLISH: Trading 1682.4% below Wall St target ($19.25)
Trading Range Analysis
30-Day Trading Range
$0.99 -
$1.07
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.98
Resistance Level
$1.11
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.39
Wall Street Target
$19.25
(+1682.4%)
Share & Embed Analysis
Last updated: July 02, 2026 11:40 PM ET
Data refreshes hourly during market hours. Next update: 12:40 AM
Data refreshes hourly during market hours. Next update: 12:40 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is REVB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 59 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 63 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 56 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$34 | 67 BUY |
